Principles of immunotherapy

Brandon D. Liebelt, Gaetano Finocchiaro, Amy B. Heimberger*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingConference contribution

9 Scopus citations


Gliomas are the most common primary brain tumors of the central nervous system, and carry a grim prognosis. Novel approaches utilizing the immune system as adjuvant therapy are quickly emerging as viable and effective options. Immunotherapeutic strategies being investigated to treat glioblastoma include: vaccination therapy targeted against either specific tumor antigens or whole tumor lysate, adoptive cellular therapy with cytotoxic T lymphocytes, chimeric antigen receptors and bi-specific T-cell engaging antibodies allowing circumvention of major histocompatibility complex restriction, aptamer therapy with aims for more efficient target delivery, and checkpoint blockade in order to release the tumor-mediated inhibition of the immune system. Given the heterogeneity of glioblastoma and its ability to gain mutations throughout the disease course, multifaceted treatment strategies utilizing multiple forms of immunotherapy in combination with conventional therapy will be most likely to succeed moving forward.

Original languageEnglish (US)
Title of host publicationGliomas, 2016
EditorsMitchel S. Berger, Michael Weller
PublisherElsevier B.V.
Number of pages19
ISBN (Print)9780128029978
StatePublished - 2016
Externally publishedYes

Publication series

NameHandbook of Clinical Neurology
ISSN (Print)0072-9752
ISSN (Electronic)2212-4152


  • Adoptive cellular therapy
  • Aptamers
  • Bi-specific T-cell engaging antibodies
  • Chimeric antigen receptors
  • Glioblastoma
  • Immune checkpoint
  • Immunology
  • Immunotherapy
  • Malignant brain tumor
  • Vaccine therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Principles of immunotherapy'. Together they form a unique fingerprint.

Cite this